0001209191-20-011824.txt : 20200221
0001209191-20-011824.hdr.sgml : 20200221
20200221200236
ACCESSION NUMBER: 0001209191-20-011824
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200121
FILED AS OF DATE: 20200221
DATE AS OF CHANGE: 20200221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kent Jeff
CENTRAL INDEX KEY: 0001769107
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35238
FILM NUMBER: 20641801
MAIL ADDRESS:
STREET 1: C/O HORIZON PHARMA PLC
STREET 2: CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD
CITY: DUBLIN
STATE: L2
ZIP: 4
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Horizon Therapeutics Public Ltd Co
CENTRAL INDEX KEY: 0001492426
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: CONNAUGHT HOUSE, 1ST FLOOR
STREET 2: 1 BURLINGTON ROAD
CITY: DUBLIN
STATE: L2
ZIP: 4
BUSINESS PHONE: 011-353-1-772-2100
MAIL ADDRESS:
STREET 1: CONNAUGHT HOUSE, 1ST FLOOR
STREET 2: 1 BURLINGTON ROAD
CITY: DUBLIN
STATE: L2
ZIP: 4
FORMER COMPANY:
FORMER CONFORMED NAME: Horizon Pharma plc
DATE OF NAME CHANGE: 20140919
FORMER COMPANY:
FORMER CONFORMED NAME: HORIZON PHARMA, INC.
DATE OF NAME CHANGE: 20100520
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0306
4/A
2020-01-21
2020-01-23
0
0001492426
Horizon Therapeutics Public Ltd Co
HZNP
0001769107
Kent Jeff
C/O HORIZON THERAPEUTICS PLC
CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD
DUBLIN
L2
4
IRELAND
0
1
0
0
See remarks
Ordinary Shares
2020-01-21
4
A
0
3045
0.00
A
114712
D
Ordinary Shares
2020-01-21
4
F
0
1349
38.25
D
113363
D
Performance Restricted Stock Units (PSUs)
2020-01-21
4
A
0
6091
0.00
A
Ordinary Shares
6091
6091
D
On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022.
Each PSU represents a contingent right to receive one ordinary share of the Issuer.
Officer Title: SVP, Head of Medical Affairs & Outcomes Research
The share amounts set forth in the original Form 4 filing were incorrect. This amended report corrects and replaces the original Form 4 filing in its entirety.
/s/ Miles W. McHugh, Attorney-in-Fact
2020-02-21